ASGR1 and Its Enigmatic Relative, CLEC10A
Overview
Chemistry
Molecular Biology
Authors
Affiliations
The large family of C-type lectin (CLEC) receptors comprises carbohydrate-binding proteins that require Ca to bind a ligand. The prototypic receptor is the asialoglycoprotein receptor-1 (ASGR1, CLEC4H1) that is expressed primarily by hepatocytes. The early work on ASGR1, which is highly specific for N-acetylgalactosamine (GalNAc), established the foundation for understanding the overall function of CLEC receptors. Cells of the immune system generally express more than one CLEC receptor that serve diverse functions such as pathogen-recognition, initiation of cellular signaling, cellular adhesion, glycoprotein turnover, inflammation and immune responses. The receptor CLEC10A (C-type lectin domain family 10 member A, CD301; also called the macrophage galactose-type lectin, MGL) contains a carbohydrate-recognition domain (CRD) that is homologous to the CRD of ASGR1, and thus, is also specific for GalNAc. CLEC10A is most highly expressed on immature DCs, monocyte-derived DCs, and alternatively activated macrophages (subtype M2a) as well as oocytes and progenitor cells at several stages of embryonic development. This receptor is involved in initiation of T1, T2, and T17 immune responses and induction of tolerance in naïve T cells. Ligand-mediated endocytosis of CLEC receptors initiates a Ca signal that interestingly has different outcomes depending on ligand properties, concentration, and frequency of administration. This review summarizes studies that have been carried out on these receptors.
Lu Y, Chen T, Lin H, Chen Y, Lin Y, Le D J Extracell Vesicles. 2025; 14(2):e70044.
PMID: 39901768 PMC: 11791321. DOI: 10.1002/jev2.70044.
Golgi protein 73: the driver of inflammation in the immune and tumor microenvironment.
Feng P, Hu X, Zhou S, Liu X, Zeng L, Liu Y Front Immunol. 2025; 15():1508034.
PMID: 39845976 PMC: 11750648. DOI: 10.3389/fimmu.2024.1508034.
Kirikovich S, Levites E, Proskurina A, Ritter G, Dolgova E, Ruzanova V Curr Issues Mol Biol. 2024; 46(10):10934-10959.
PMID: 39451530 PMC: 11506609. DOI: 10.3390/cimb46100650.
Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.
Zhang X, Wu Y, Lin J, Lu S, Lu X, Cheng A Acta Pharm Sin B. 2024; 14(9):3818-3833.
PMID: 39309492 PMC: 11413705. DOI: 10.1016/j.apsb.2024.05.013.
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation.
Skeeters S, Bagale K, Stepanyuk G, Thieker D, Aguhob A, Chan K Mol Ther Methods Clin Dev. 2024; 32(3):101301.
PMID: 39185275 PMC: 11342882. DOI: 10.1016/j.omtm.2024.101301.